NEUP
Neuphoria Therapeutics Inc. Common StockNEUP
NEUP
0
Funds holding %
of 7,390 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
0.11% less ownership
Funds ownership: 0.12% [Q3] → 0% (-0.11%) [Q4]
11% less funds holding
Funds holding: 9 [Q3] → 8 (-1) [Q4]
17% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 6
75% less capital invested
Capital invested by funds: $1.1M [Q3] → $273K (-$826K) [Q4]
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 3
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$21
262%
upside
Avg. target
$21
262%
upside
High target
$21
262%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Joseph Pantginis 23% 1-year accuracy 95 / 411 met price target | 262%upside $21 | Buy Maintained | 4 Feb 2025 |
Financial journalist opinion
Neutral
GlobeNewsWire
3 weeks ago
Neuphoria Therapeutics to Ring the Nasdaq Opening Bell on March 3rd, 2025
BURLINGTON, Mass., March 03, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (Nasdaq: NEUP) (Neuphoria or Company), ”), a clinical-stage biotechnology developing impactful treatments for neuropsychiatric disorders, bringing new hope and tangible improvements to patients' lives, announced today that it will ring the Opening Bell at the Nasdaq MarketSite in Times Square, New York City on Monday, March 3rd, 2025.
Neutral
GlobeNewsWire
1 month ago
Neuphoria Therapeutics Inc. to Receive $15M Milestone Payment from Merck
Milestone payment triggered by the initiation of a Phase 2 clinical trial in Alzheimer's disease with MK-1167, an α7 nicotinic acetylcholine receptor positive allosteric modulator Milestone payment triggered by the initiation of a Phase 2 clinical trial in Alzheimer's disease with MK-1167, an α7 nicotinic acetylcholine receptor positive allosteric modulator
Positive
Zacks Investment Research
1 month ago
Here's Why Momentum in Neuphoria Therapeutics Inc. (NEUP) Should Keep going
If you are looking for stocks that are well positioned to maintain their recent uptrend, Neuphoria Therapeutics Inc. (NEUP) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Neutral
GlobeNewsWire
3 months ago
Neuphoria Completes Re-domiciliation and Successor Listing on Nasdaq
BURLINGTON, Mass., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (Nasdaq: NEUP) (“Neuphoria” or the “Company”) is pleased to announce that its previously announced scheme of arrangement in relation to Bionomics Limited's proposed re-domiciliation from Australia to the United States, under which Neuphoria will become the ultimate parent company of Bionomics Limited, has been implemented today, December 23, 2024 New York time (December 24, 2024 Sydney time).
Charts implemented using Lightweight Charts™